Cargando…
Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma
Primary effusion lymphoma (PEL) is caused by Kaposi’s sarcoma-associated herpesvirus (KSHV). PEL has a highly active mTOR pathway, which makes mTOR a potential therapeutic target. MLN0128 is an ATP-competitive inhibitor of mTOR that has entered clinical trials for solid tumors. Our results demonstra...
Autores principales: | Caro-Vegas, Carolina, Bailey, Aubrey, Bigi, Rachele, Damania, Blossom, Dittmer, Dirk P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381283/ https://www.ncbi.nlm.nih.gov/pubmed/30782662 http://dx.doi.org/10.1128/mBio.02871-18 |
Ejemplares similares
-
Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth
por: Kannan, Aarthi, et al.
Publicado: (2015) -
MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells
por: Zeng, Zhihong, et al.
Publicado: (2016) -
Determinants of mTOR inhibitor therapy in AIDS-associated malignancies
por: Dittmer, Dirk P, et al.
Publicado: (2012) -
Combined Inhibition of Akt and mTOR Is Effective Against Non-Hodgkin Lymphomas
por: Rivera-Soto, Ricardo, et al.
Publicado: (2021) -
AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
por: Bhatt, Aadra P., et al.
Publicado: (2013)